EM1606G "Heart Failure with Preserved Ejection Fraction: Learning from Failure" (IM GR-061016)
Heart failure with preserved ejection fraction (HFpEF) has been a vexing disease for internists, cardiologists and geriatricians. The high prevalence and lack of evidenced based therapies makes management of this syndrome very challenging for both clinicians and patients. A number of clinical trials have applied treatment paradigms that have been successful in treating heart failure with reduced ejection fraction (HFrEF). Unfortunately, therapies centered on neuro-hormonal blockade have no benefit on morbidity or mortality in HFpEF. The reasons for the lack of benefit are not entirely clear but likely reflect the vastly different pathologic remodeling that occurs with the heart. This review will identify gaps in our current understanding of the epidemiology and patho-physiology in HFpEF as well as preview future directions for HFpEF therapy.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Characterize the differences in ventricular remodeling between HFpEF and HFrEF
- Describe the factors that lead to increased arterial and ventricular stiffness
- Understand the numerous diagnostic dilemmas and pitfalls for diagnosing HFpEF
- Describe the rationale for using nitrates in the management of HFpEF exercise intolerance
Satyam (Tom) Sarma, M.D.
Division of Cardiology
- 1.00 AMA